7 Signs of lupus activity in other body systems support the diagnosis. In the patient presented here, the presence of seizures, elevated anti-dsDNA antibodies, low complement C3 levels ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

RubrYc’s lead programs include RTX-002, an anti-PD-1 agonist for serious autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, and RTX-003, an anti-CD25 antibody that ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Two other immunologic markers were recognized in the 1950s as being associated with lupus: the biologic false-positive test for syphilis and the immunofluorescent test for antinuclear antibodies.

Systemic Lupus Erythematosus (SLE)-lupus for short-is a chronic, painful and debilitating disease in which the antibodies produced by the immune system mistakenly attack the body's own tissues.

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Systemic Lupus Erythematosus (SLE)—lupus for short—is a chronic, painful and debilitating disease in which the antibodies produced by the immune system mistakenly attack the body's own tissues.

Read More: The Most Exciting New Advancements in Managing and Treating Lupus In response to a threat, such as a virus or other pathogen, the immune system produces protein antibodies that are ...

Type B insulin resistance syndrome can develop when autoimmune antibodies or autoantibodies in lupus attack insulin receptor sites. While this primarily results in severe hyperglycemia (elevated ...